NASDAQ: MLECMoolec Science Sa Stock
$0.72+0.08 (+12.5%)
Updated Apr 29, 2025
MLEC Price
$0.72
Fair Value Price
N/A
Market Cap
$28.80M
52 Week Low
$0.53
52 Week High
$1.45
P/E
-3.43x
P/B
10.3x
P/S
3.93x
PEG
N/A
Dividend Yield
N/A
Revenue
$7.83M
Earnings
-$8.28M
Gross Margin
-8.2%
Operating Margin
-82.22%
Profit Margin
-105.7%
Debt to Equity
10.22
Operating Cash Flow
-$6M
Beta
0.38
Next Earnings
May 28, 2025
Ex-Dividend
N/A
Next Dividend
N/A
MLEC Overview
LightJump Acquisition Corporation is a 'blank check' company formed to effect mergers, stock purchases, or similar combinations with one or more businesses. It targets the tech sector. LightJump Acquisition was incorporated in 2020 and is headquartered in Menlo Park, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MLEC's potential to beat the market
- MLEC doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MLEC
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.96 | A | |
| $8.12 | A | |
| $24.28 | A |
Be the first to know about important MLEC news, forecast changes, insider trades & much more!
MLEC News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MLEC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MLEC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MLEC is poor value based on its book value relative to its share price (10.3x), compared to the US Biotechnology industry average (4.37x)
P/B vs Industry Valuation
MLEC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MLEC due diligence checks available for Premium users.
Valuation
MLEC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.43x
Industry
-158.75x
Market
29.19x
MLEC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.3x
Industry
4.37x
MLEC is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MLEC's financial health
Profit margin
Revenue
$2.6M
Net Income
-$2.4M
Profit Margin
-91.8%
MLEC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MLEC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$31.4M
Liabilities
$28.6M
Debt to equity
10.22
MLEC's short-term assets ($9.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MLEC's long-term liabilities ($22.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MLEC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$890.5k
Investing
-$298.9k
Financing
-$529.9k
MLEC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MLEC vs Biotech Stocks
Moolec Science Sa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.